CA2345753A1 - Procede pour augmenter l'excretion des substances hydrophobes endogenes autres que les sterols en augmentant l'excretion fecale des matieres grasses - Google Patents
Procede pour augmenter l'excretion des substances hydrophobes endogenes autres que les sterols en augmentant l'excretion fecale des matieres grasses Download PDFInfo
- Publication number
- CA2345753A1 CA2345753A1 CA002345753A CA2345753A CA2345753A1 CA 2345753 A1 CA2345753 A1 CA 2345753A1 CA 002345753 A CA002345753 A CA 002345753A CA 2345753 A CA2345753 A CA 2345753A CA 2345753 A1 CA2345753 A1 CA 2345753A1
- Authority
- CA
- Canada
- Prior art keywords
- compound
- excretion
- fat
- accumulation
- faeces
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/739—Lipopolysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Toxicology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Cette invention se rapporte à un procédé servant à augmenter l'excrétion des substances hydrophobes endogènes autres que les stérols ou des dérivés métaboliques de cette substance, en augmentant l'excrétion fécale de ces substances hydrophobes ou des dérivés métaboliques de celles-ci, ce procédé se caractérisant en ce que l'excrétion fécale des matières grasses est accrue. Le but de cette invention est de prévenir ou de traiter les états associés à l'accumulation de substances hydrophobes endogènes autres que les stérols ou de dérivés métaboliques de ces substances, ces substances étant la bilirubine ou la protoporphyrine non conjuguée. Plus particulièrement, la lipstatine, l'orlistat, la tétrahydrolipstatine, les acides gras de polyol tels que l'olestra et les doses non habituelles de matières grasses diététiques sont utilisées pour traiter l'ictère physiologique du nouveau-né, l'ictère hémolytique et la protoporphyrie érythropoiétique.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/NL1999/000492 WO2001008679A1 (fr) | 1999-07-30 | 1999-07-30 | Procede pour augmenter l'excretion des substances hydrophobes endogenes autres que les sterols en augmentant l'excretion fecale des matieres grasses |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2345753A1 true CA2345753A1 (fr) | 2001-02-08 |
Family
ID=19866607
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002345753A Abandoned CA2345753A1 (fr) | 1999-07-30 | 1999-07-30 | Procede pour augmenter l'excretion des substances hydrophobes endogenes autres que les sterols en augmentant l'excretion fecale des matieres grasses |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP1117396A1 (fr) |
JP (1) | JP2003505504A (fr) |
AU (1) | AU5200299A (fr) |
CA (1) | CA2345753A1 (fr) |
WO (1) | WO2001008679A1 (fr) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1216625A1 (fr) * | 2000-12-21 | 2002-06-26 | The Procter & Gamble Company | Utilisation d'un lipide non-digestible, non-absorbable pour le traitement de l'hyperbilirubinémie |
JP5697296B2 (ja) | 2004-03-05 | 2015-04-08 | ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア | 高脂血症および高コレステロール血症に関連する障害または疾患を、副作用を最小限にしつつ処置するための方法 |
US20130115306A1 (en) * | 2011-11-09 | 2013-05-09 | Denovo Inc. | Toxin decontaminant food product and method of treating disorders of the gastrointestinal tract |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4363801A (en) * | 1981-02-09 | 1982-12-14 | The Texas A&M University System | Method for treating hyperbilirubinemia |
AU570143B2 (en) * | 1985-01-14 | 1988-03-03 | Rockefeller University, The | Method of increasing heme excretion from a mammal using tin protoporphyrin |
WO1989006137A1 (fr) * | 1988-01-11 | 1989-07-13 | Massachusetts Institute Of Technology | Therapie orale de reduction de la bilirubine |
US5665775A (en) * | 1995-07-28 | 1997-09-09 | Arab Pharmaceutical Manufacturing Co., Ltd. | Different way of management of neonatal hyperbilirubinemia |
JPH10330265A (ja) * | 1997-06-02 | 1998-12-15 | Lederle Japan Ltd | 肝疾患治療剤 |
-
1999
- 1999-07-30 CA CA002345753A patent/CA2345753A1/fr not_active Abandoned
- 1999-07-30 JP JP2001513409A patent/JP2003505504A/ja active Pending
- 1999-07-30 AU AU52002/99A patent/AU5200299A/en not_active Abandoned
- 1999-07-30 WO PCT/NL1999/000492 patent/WO2001008679A1/fr not_active Application Discontinuation
- 1999-07-30 EP EP99937113A patent/EP1117396A1/fr not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
JP2003505504A (ja) | 2003-02-12 |
AU5200299A (en) | 2001-02-19 |
WO2001008679A1 (fr) | 2001-02-08 |
EP1117396A1 (fr) | 2001-07-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20200297625A1 (en) | Dimethyl sulfoxide (dmso) and methylsulfonylmethane (msm) formulations to treat osteoarthritis | |
US11331302B2 (en) | Transmucosal delivery of tocotrienol | |
US20080234362A1 (en) | Treatment for Asthma and Arthritis and Other Inflammatory Diseases | |
US5230996A (en) | Use of ascorbate and tranexamic acid solution for organ and blood vessel treatment prior to transplantation | |
AU2004210244B2 (en) | Oils enriched with diacylglycerols and phytosterol esters for use in the reduction of cholesterol and triglycerides | |
Ullrich | Evaluation of a high-fiber diet in hyperlipidemia: a review. | |
AU679818B2 (en) | Butyric ester cyto-differentiating agents | |
Wathne et al. | Retinol bound to physiological carrier molecules regulates growth and differentiation of myeloid leukemic cells. | |
CA2345753A1 (fr) | Procede pour augmenter l'excretion des substances hydrophobes endogenes autres que les sterols en augmentant l'excretion fecale des matieres grasses | |
Sirtori et al. | Mechanisms of lipid-lowering agents | |
Lukovac et al. | Gelucire® 44/14 improves fat absorption in rats with impaired lipolysis | |
US5411748A (en) | Prostate extract supplemented with zinc | |
Geremias et al. | Lipid lowering activity of hydrosoluble chitosan and association with Aloe vera L. and Brassica olearaceae L. | |
US6476010B2 (en) | Method for increasing intestinal absorption of fat soluble vitamins in post-menopausal women and lower animals | |
US5942500A (en) | Dietary composition to reduce dietary fats | |
US20030133965A1 (en) | Application of phytosterols (and their isomers), folic acid, cyanocobalamin and pyridoxin in dietetic (alimentary) fibers | |
AU2001249106A1 (en) | Method for increasing intestinal absorption of fat soluble vitamins in post-menopausal women and lower animals | |
EP0354818A2 (fr) | Compositions pharmaceutiques renfermant des composés polyaromatiques comme agents actifs et leur emploi | |
US6998397B2 (en) | Method for decreasing cholesterol level in blood | |
CA1117041A (fr) | Complexe lipoproteique normalisant l'efficacite de la vitamine e et des antioxydants de synthese | |
Hsiang et al. | Intraluminal endothelium-covered bridges in chronic fat-fed balloon-injured Yucatan miniswine | |
CH635749A5 (en) | Lipoprotein complex which regularises the efficacy of vitamin E and synthetic antioxidants | |
WO2008101923A1 (fr) | Utilisation de dérivés d'acide panthothénique destinés au traitement de l'hypophosphatémie | |
WO2014042448A1 (fr) | Composition pour la prévention ou le traitement de maladies du foie contenant de la phosphatidylcholine et du biphényl diméthyl dicarboxylate, et son utilisation | |
ZA200207235B (en) | Method for increasing intestinal absorption of fat soluble vitamins in post-menopausal women and lower animals. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FZDE | Discontinued | ||
FZDE | Discontinued |
Effective date: 20050801 |